The estimated Net Worth of Richard A Lerner is at least $7.51 Milion dollars as of 11 May 2020. Richard Lerner owns over 25,000 units of Intra-Cellular Therapies Inc stock worth over $7,271,227 and over the last 17 years he sold ITCI stock worth over $0. In addition, he makes $237,720 as Independent Director at Intra-Cellular Therapies Inc.
Sign up
Richard Lerner ITCI stock SEC Form 4 insiders trading
Richard has made over 16 trades of the Intra-Cellular Therapies Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of ITCI stock worth $68,500 on 11 May 2020.
The largest trade he's ever made was buying 50,000 units of Intra-Cellular Therapies Inc stock on 16 May 2012 worth over $230,000. On average, Richard trades about 4,405 units every 39 days since 2007. As of 11 May 2020 he still owns at least 97,313 units of Intra-Cellular Therapies Inc stock.
You can see the complete history of Richard Lerner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Lerner biography
Dr. Richard A. Lerner M.D. is an Independent Director of Intra-Cellular Therapies, Inc. Dr. Lerner became a director of the Company following the Merger that occurred in August 2013 and has served on the board of directors of ITI since 2002. Dr. Lerner served as President of the Scripps Research Institute, a private, non-profit biomedical research organization from 1986 to January 2012, and since then has served and continues to serve as Institute Professor. Dr. Lerner received the Wolf Prize in Chemistry in 1994, the California Scientist of the Year Award in 1996, the Paul Ehrlich and Ludwig Darmstaedter Prize in 2003, and the Prince of Asturias Award in 2012 for his achievements in the development of catalytic antibodies and combinatorial antibody libraries. Dr. Lerner is a member of the National Academy of Sciences and the Royal Swedish Academy of Sciences. Dr. Lerner previously served as a director of Kraft Foods, Inc. and Teva Pharmaceutical Industries Ltd. and currently serves as a director of Opko Health, Inc., a publicly-traded biotechnology company and Zebra Biologics, Cognos Therapeutics and Interex, Inc. which are private companies. Dr. Lerner received his M.D. from Stanford Medical School.
What is the salary of Richard Lerner?
As the Independent Director of Intra-Cellular Therapies Inc, the total compensation of Richard Lerner at Intra-Cellular Therapies Inc is $237,720. There are 15 executives at Intra-Cellular Therapies Inc getting paid more, with Sharon Mates having the highest compensation of $4,724,560.
How old is Richard Lerner?
Richard Lerner is 81, he's been the Independent Director of Intra-Cellular Therapies Inc since 2014. There are no older and 16 younger executives at Intra-Cellular Therapies Inc.
What's Richard Lerner's mailing address?
Richard's mailing address filed with the SEC is C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK, NY, 10016.
Insiders trading at Intra-Cellular Therapies Inc
Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over $77,703,646 worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth $52,322,638 . The most active insiders traders include Rory B Riggs, Joel S Marcus oraz Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,787,280. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth $891,100.
What does Intra-Cellular Therapies Inc do?
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
What does Intra-Cellular Therapies Inc's logo look like?
Complete history of Richard Lerner stock trades at Intra-Cellular Therapies Inc i Opko Health Inc
Intra-Cellular Therapies Inc executives and stock owners
Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:
-
Sharon Mates,
Chairman of the Board, President, Chief Executive Officer -
Mark Neumann,
Executive Vice President, Chief Commercial Officer -
Michael Halstead,
Executive Vice President, General Counsel and Secretary -
Lawrence Hineline,
Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary -
Robert Davis,
Senior Vice President and Chief Scientific Officer -
Kimberly Vanover,
Senior Vice President, Early Stage Clinical Development and Translational Medicines -
Dr. Sharon Mates,
Co-Founder, Chairman, CEO & Pres -
Mark Neumann,
EVP & Chief Commercial Officer -
Michael I. Halstead J.D.,
Exec. VP, Gen. Counsel & Sec. -
Dr. Suresh K. Durgam M.D.,
Sr. VP & Chief Medical Officer -
Lawrence J. Hineline CPA, CPA,
Sr. VP of Fin., CFO, Treasurer & Assistant Sec. -
Robert Van Nostrand,
Lead Independent Director -
Joel Marcus,
Independent Director -
Christopher Alafi,
Independent Director -
Rory Riggs,
Independent Director -
Richard Lerner,
Independent Director -
Michael Olchaskey,
Senior Vice President, Head of Regulatory Affairs -
Suresh Durgam,
Chief Medical Officer -
John Bardi,
Senior Vice President - Market Access, Policy and Government Affairs -
Karen Patruno Sheehy Esq.,
Sr. VP & Chief Compliance Officer -
Juan Fernando Sanchez,
VP of Corp. Communications & Investor Relations -
Dr. Robert E. Davis Ph.D.,
Sr. VP & Chief Scientific Officer -
Moshe Alafi,
10% owner -
Capital Co Llc Alafi,
10% owner -
Juan F. Sanchez,
VP, Corp. Communications & IR -
Allen A. Fienberg,
VP of Business Development -
Lawrence P. Wennogle,
Vice President, Drug Discovery -
Michael Rawlins,
Director -
Eduardo Rene Salas,
-
Sanjeev Narula,
Executive Vice President & CFO